AI Summary & Key Takeaways
AI InsightObjective: To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer.Materials and Methods: Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated.Results: The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months.
📌 3 Key Takeaways
Abstract
Objective: To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer.Materials and Methods: Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated.Results: The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months. All 64 patients received a median of 6 (range, 1-12) bevacizumab and 6 (range, 2-12) chemotherapy cycles. The chemotherapy regimens used with bevacizumab were cisplatin and paclitaxel in 31 (48%) and carboplatin and paclitaxel in 33 (52%) patients. The survival in patients treated with bevacizumab and cisplatin plus paclitaxel was better-particularly in patients with no previous cisplatin-based radiosensitizer therapy-than those treated with carboplatin, paclitaxel, and bevacizumab (p=0.023). The bevacizumab dose was 7.5 mg/kg in 30 patients (47%) and 15 mg/kg in 34 patients (53%) every 21 days. No significant difference was reported in the OS and the PFS between the two groups. While the most common all-grades adverse events were nausea, neutropenia, anemia, and peripheral sensory neuropathy, the most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy.Conclusion: Adding bevacizumab to platinum and paclitaxel chemotherapy in a case of metastatic or recurrent cervical cancer is an effective and tolerable treatment for Turkish patients.
Özet
Amaç: Monoklonal, antivasküler endotelyal büyüme faktörü antikoru olan bevasizumabın sitotoksik kemoterepilerle birlikte kullanımının metastatik,tekrarlayan serviks kanserli Türk hasta popülasyonunda etkinliğini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Metastatik, tekrarlayan serviks kanseri tanısıyla 2013 ve 2017 yılları arasında ilk seri tedavide sisplatin veya carboplatin ve paklitakselkemoterapisi ile bevasizumab kullanan hastaların dosyalarını geriye dönük olarak inceledik. Bulgular: Altmış dört hastanın verisini değerlendirdik. Ortalama yaş 49 (aralık, 28-68), ortanca takip süresi 12 aydı (aralık, 2-53), ortanca progresyonsuzsağkalım süresi 8 ay ve ortanca genel sağkalım süresi 23 aydı. Ortanca bevasizumab ve kemoterapi kür sayısı altı idi. Bevasizumab ile birlikte kullanılankemoterapi rejimleri 31 hastada (4%8) sisplatin ve paklitaksel, 33 hastada (%52) karboplatin, ve paklitakseldi. Daha önce radyoterapi duyarlılaştırıcı olaraksisplatin almayan hastalarda sağkalım süresi sisplatinli tedavi alan hastalarda karboplatinli tedaviden daha iyiydi (p=0,023). Bevasizumab dozu 30 hastada(%47) 7,5 mg/kg ve 34 hastada (%53) 15 mg/kg 21 günde bir idi. İki grup arasında genel sağkalım ve progresyonsuz sağkalım farkı yoktu. Tüm gradlardaen sık görülen yan etkiler bulantı, nötropeni, anemi ve periferal duysal nöropati, en sık görülen grad ≥3 yan etkiler ise nötropeni, anemi ve periferal duysalnöropatiydi. Sonuç: Metastatik ve tekrarlayan serviks kanserli Türk hasta popülasyonunda platin ve bevasizumab tedavisi etkin ve güvenli bir tedavidir.